[改善病情抗风湿药（聚焦于艾拉莫德）]
[DMARDs (Focusing on iguratimod)].
作者信息
Ito Satoshi
出版信息
Nihon Rinsho. 2016 Jun;74(6):948-54.
Conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) other than methotrexate (MTX: anchor csDMARDs) are effective for single use, reinforcement of MTX, biologics and induction and maintenance of biologics-free condition. Newly developed iguratimod (IGU) does not suppress immunological reaction, therefore, it is useful for single use or combination with other csDMARDs in patients with complications. IGU can be used as a first csDMARDs before MTX use during the screening for MTX. IGU might be effective for reinforcement of MTX, biologics and induction and maintenance of biologics-free condition just like other csDMARDs. IGU can be used in wide variety of situation of the treatment of rheumatoid arthritis and it is desired that after the all-case surveillance condition for approval, IGU become a standard csDMARDs all over the world which was made in Japan.
除甲氨蝶呤（MTX：核心传统合成病情改善抗风湿药）外，其他传统合成病情改善抗风湿药（csDMARDs）单药使用、强化MTX治疗、生物制剂治疗以及诱导和维持无生物制剂状态均有效。新研发的艾拉莫德（IGU）并不抑制免疫反应，因此，对于有并发症的患者，它可单药使用或与其他csDMARDs联合使用。在筛选MTX期间，IGU可在使用MTX之前作为首个csDMARDs使用。IGU可能像其他csDMARDs一样，对强化MTX治疗、生物制剂治疗以及诱导和维持无生物制剂状态有效。IGU可用于类风湿关节炎治疗的多种情况，期望在批准的全病例监测情况之后，IGU成为全球标准的由日本制造的csDMARDs。
Zotero 插件